California health centers asked a federal district judge yesterday to stop a major state Medicaid drug reimbursement change due to begin tomorrow. They say the change would strip away all their 340B drug discount savings, devastating safety-net health care
…
U.S. Sen. Joe Manchin (D-W.Va.) has suggested that the U.S. Department of Veterans Affairs (VA) be empowered to negotiate drug prices on behalf of Medicare, an initiative that may impact the 340B program if it should come to fruition.
Manchin
…Boston-based par8o, which provides 340B services including a platform to help 340B covered entities manage their patient referral claims, has been acquired by Cloudmed.
Cloudmed is a revenue intelligence company based in Atlanta. The company partners with over 3,100 healthcare
…
The U.S. House Oversight and Reform Committee issued a blistering report late last week accusing brand pharmaceutical manufacturers of systematically jacking up prices on their drugs in the United States.
Pharmaceutical Research and Manufacturers of America (PhRMA) called it a
…
As California’s Medicaid program moves toward implementing a fee-for-service payment structure for drug coverage, one of the primary foes of the transition has returned to court to obtain a temporary restraining order.
The new Medi-Cal Rx program is intended to
…
Three drug manufacturers recently announced they are refunding 340B overpayments to covered entities, part of a growing number of companies that have disclosed they miscalculated the pricing of their products.
The U.S. Health Resources and Services Administration posted GlaxoSmithKline,
…
340B hospitals’ challenge to Medicare Part B drug reimbursement cuts was not the only case on the U.S. Supreme Court docket this week that could have a significant impact on the program.
On Monday, the justices heard the case of
…
After five major court decisions on the 340B contract pharmacy standoff and no quick resolution in sight, expect Congress to end the fight over contract pharmacy before the 2022 midterm elections, 340B Report Publisher and CEO Ted Slafsky predicts in
…
Makers of seven of 10 top drugs in the U.S. hiked those drugs’ prices substantially in 2020 with no new evidence of improved safety or effectiveness, led by AbbVie’s anti-inflammatory blockbuster Humira, an influential drug pricing watchdog group says.
The
…
*Sign up for news summaries and alerts from 340B Report